Longitudinal studies of cellular immunity of patients with osteogenic sarcoma during chemoimmunotherapy

H. F. Sears, R. Simon, S. A. Rosenberg

Research output: Contribution to journalArticle

Abstract

The cellular immune reactivity of 24 patients with osteogenic sarcoma was studied longitudinally during surgical treatment ans subsequent adjuvant chemoimmunotherapy. Cellular immune function was studied using in vitro assays of lymphocyte reactivity to mitogens and nonspecific allogenic antigens. Circulating cells were characterized by the total lymphocyte and wbc counts, determination of E-rosetting populations, and percent of polymorphonuclear leukocytes. Both fresh and cryopreserved lymphocytes were utilized and compared. The preoperative values from these studies offered no useful indication of those patients likely to have disease recurrence. Likewise, longitudinal studies during the course of adjuvant treatment did not predict relapse before other routine clinical studies could identify it. There was no difference in the studied lymphocyte functions and hematologic tests between the group receiving BCG immunotherapy and those not receiving BCG. Our studies indicate that current measures of cellular immune function are of little value in the monitoring of patients with osteogenic sarcoma.

Original languageEnglish (US)
Pages (from-to)589-592
Number of pages4
JournalCancer Treatment Reports
Volume64
Issue number4-5
StatePublished - 1980
Externally publishedYes

Fingerprint

Osteosarcoma
Cellular Immunity
Longitudinal Studies
Lymphocytes
Mycobacterium bovis
Recurrence
Lymphocyte Count
Physiologic Monitoring
Hematologic Tests
Mitogens
Immunotherapy
Neutrophils
Antigens
Therapeutics
Population

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Longitudinal studies of cellular immunity of patients with osteogenic sarcoma during chemoimmunotherapy. / Sears, H. F.; Simon, R.; Rosenberg, S. A.

In: Cancer Treatment Reports, Vol. 64, No. 4-5, 1980, p. 589-592.

Research output: Contribution to journalArticle

Sears, H. F. ; Simon, R. ; Rosenberg, S. A. / Longitudinal studies of cellular immunity of patients with osteogenic sarcoma during chemoimmunotherapy. In: Cancer Treatment Reports. 1980 ; Vol. 64, No. 4-5. pp. 589-592.
@article{f57f51b4109a4307adb50119408ff8dc,
title = "Longitudinal studies of cellular immunity of patients with osteogenic sarcoma during chemoimmunotherapy",
abstract = "The cellular immune reactivity of 24 patients with osteogenic sarcoma was studied longitudinally during surgical treatment ans subsequent adjuvant chemoimmunotherapy. Cellular immune function was studied using in vitro assays of lymphocyte reactivity to mitogens and nonspecific allogenic antigens. Circulating cells were characterized by the total lymphocyte and wbc counts, determination of E-rosetting populations, and percent of polymorphonuclear leukocytes. Both fresh and cryopreserved lymphocytes were utilized and compared. The preoperative values from these studies offered no useful indication of those patients likely to have disease recurrence. Likewise, longitudinal studies during the course of adjuvant treatment did not predict relapse before other routine clinical studies could identify it. There was no difference in the studied lymphocyte functions and hematologic tests between the group receiving BCG immunotherapy and those not receiving BCG. Our studies indicate that current measures of cellular immune function are of little value in the monitoring of patients with osteogenic sarcoma.",
author = "Sears, {H. F.} and R. Simon and Rosenberg, {S. A.}",
year = "1980",
language = "English (US)",
volume = "64",
pages = "589--592",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "4-5",

}

TY - JOUR

T1 - Longitudinal studies of cellular immunity of patients with osteogenic sarcoma during chemoimmunotherapy

AU - Sears, H. F.

AU - Simon, R.

AU - Rosenberg, S. A.

PY - 1980

Y1 - 1980

N2 - The cellular immune reactivity of 24 patients with osteogenic sarcoma was studied longitudinally during surgical treatment ans subsequent adjuvant chemoimmunotherapy. Cellular immune function was studied using in vitro assays of lymphocyte reactivity to mitogens and nonspecific allogenic antigens. Circulating cells were characterized by the total lymphocyte and wbc counts, determination of E-rosetting populations, and percent of polymorphonuclear leukocytes. Both fresh and cryopreserved lymphocytes were utilized and compared. The preoperative values from these studies offered no useful indication of those patients likely to have disease recurrence. Likewise, longitudinal studies during the course of adjuvant treatment did not predict relapse before other routine clinical studies could identify it. There was no difference in the studied lymphocyte functions and hematologic tests between the group receiving BCG immunotherapy and those not receiving BCG. Our studies indicate that current measures of cellular immune function are of little value in the monitoring of patients with osteogenic sarcoma.

AB - The cellular immune reactivity of 24 patients with osteogenic sarcoma was studied longitudinally during surgical treatment ans subsequent adjuvant chemoimmunotherapy. Cellular immune function was studied using in vitro assays of lymphocyte reactivity to mitogens and nonspecific allogenic antigens. Circulating cells were characterized by the total lymphocyte and wbc counts, determination of E-rosetting populations, and percent of polymorphonuclear leukocytes. Both fresh and cryopreserved lymphocytes were utilized and compared. The preoperative values from these studies offered no useful indication of those patients likely to have disease recurrence. Likewise, longitudinal studies during the course of adjuvant treatment did not predict relapse before other routine clinical studies could identify it. There was no difference in the studied lymphocyte functions and hematologic tests between the group receiving BCG immunotherapy and those not receiving BCG. Our studies indicate that current measures of cellular immune function are of little value in the monitoring of patients with osteogenic sarcoma.

UR - http://www.scopus.com/inward/record.url?scp=0019219972&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019219972&partnerID=8YFLogxK

M3 - Article

VL - 64

SP - 589

EP - 592

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 4-5

ER -